摘要
通过观察131I治疗前后Graves病(GD)患者TGAb、TMAb及TRAb浓度变化,探讨复方甲亢片配合131I治疗对GD患者的免疫功能的影响。将121例GD患者分为:(1)对照组:单纯131I治疗组58例,采用131I一次性口服治疗;(2)研究组:131I加复方甲亢片治疗组61例。于治疗后2、4、12个月随访患者,比较两组治疗后TGAb、TMAb、TRAb浓度的变化。结果表明治疗前研究组和对照组TGAb、TMAb阳性者分别有9例和8例,治疗后12个月时TGAb、TMAb转阴率分别为44.4%(4/9)和12.5%(1/8),研究组的转阴率高于对照组(P<0.05);两组治疗后2、4、12个月时TRAb值均逐渐下降,以4、12个月时较治疗前下降明显(P<0.05),12个月时研究组TRAb值较对照组下降明显(P<0.05),但2、4个月时两组TRAb值无明显差异(P>0.05)。复方甲亢片配合131I治疗能提高患者TGAb、TMAb的转阴率,较快地降低TRAb值,复方甲亢片具有增强GD患者机体免疫调节功能的作用。
To explore the immune effect of fufangjiakang tablets （FJT） on the treatment of Graves＇ disease with ^131I by observing the changes of serum TGAb, TMAb and TRAb levels before or after ^131I treatment, 121 patients with Graves＇ disease were divided into two groups, 58 patients treated with ^131I alone as control group and 61 patients treated with ^131I combined and FJT as research group. The patients were followed up in 2, 4 and 12 months after treatment. The levels of serum TGAb, TMAb and TRAb in patients were measured before and after treatment. The results showed that the positive cases of TGAb and TMAb in research and control group before the treatment were 9 and 8 cases separately, the cases of TGAb and TMAb changed to negative were 4 （44.4%） and 1 （12.5%） after treatment of 12 months. The rate in research group was higher than that in control group （P〈0. 05）. The TRAb levels in two groups after 2,4 and 12 months of treatment were decreased gradually. The TRAb levels between two groups had no significantly difference after 2 and 4 months of treatment, but it decreased more obviously in research group after 12 months （P〈0.05）. The combined treatment of Graves＇ disease with ^131I and FJT could increase the negative rates of TGAb and TMAb levels in patients, and reduce the levels of TRAb more quickly. Therefore it could reinforce the immune regulating function of the patients with Graves＇ disease.
出处
《标记免疫分析与临床》
CAS
2007年第2期90-92,112,共4页
Labeled Immunoassays and Clinical Medicine
